{
  "abstract": "In the primary analysis of ANDROMEDA, addition of subcutaneous daratumumab to VCd (bortezomib, cyclophosphamide, and dexamethasone; D-VCd) significantly improved hematologic complete response (CR) rate vs VCd, establishing D-VCd as the only approved therapy for light-chain (AL) amyloidosis. We present results from the preplanned final analysis. In this phase 3 trial, we randomly assigned 388 patients with newly diagnosed AL amyloidosis to 6 cycles of VCd alone (control group) or with subcutaneous daratumumab (D-VCd) followed by single-agent daratumumab every 4 weeks for up to 24 total cycles. The primary end point was hematologic CR. The updated hematologic CR rate was 59.5% for D-VCd vs 19.2% for VCd (odds ratio, 6.03; 95% confidence interval [CI], 3.80-9.58; P< .0001). Median time to hematologic CR was shorter with D-VCd (67.5 days [range, 8.0-879.0]) vs VCd (85.0 days [range, 14.0-617.0]). With a median follow-up of 61.4 months, significant improvement was observed with D-VCd vs VCd in major organ deterioration-progression-free survival (hazard ratio, 0.44; 95% CI, 0.31-0.63; P< .0001) and overall survival (hazard ratio, 0.62; 95% CI, 0.42-0.90; P = .0121). Cardiac and renal response rates were 2 to 3 times higher with D-VCd vs VCd. Achieving hematologic or cardiac CR was associated with improved major organ deterioration-progression-free survival and overall survival. Adverse events were consistent with the known safety profiles for VCd and daratumumab. Adding daratumumab to VCd resulted in deeper and more rapid hematologic responses and organ function recovery, translating to statistically significant improvement in both overall survival and major organ deterioration-progression-free survival in newly diagnosed AL amyloidosis. This trial was registered at www.clinicaltrials.gov as #NCT03201965.",
  "abstract_shown": true,
  "affiliations": [
    "1Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece",
    "2Department of Molecular Medicine, University of Pavia, Pavia, Italy",
    "3Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy",
    "4Department of Hematology, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands",
    "5University College London Hospital and National Amyloidosis Centre, University College London Royal Free Campus, London, United Kingdom",
    "6Reference Center for Amyloid Light-chain Amyloidosis, Limoges, France",
    "7Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX",
    "8Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA",
    "9Department of Haematology, Princess Alexandra Hospital and University of Queensland Medical School, Brisbane, Australia",
    "10Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China",
    "11Universitätsklinikum Heidelberg Medizinische Klinik V, Heidelberg, Germany",
    "12Hadassah Medical Center, Jerusalem, Israel",
    "13Japanese Red Cross Medical Center, Tokyo, Japan",
    "14Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea",
    "15Amyloidosis and Myeloma Unit, Hospital Clinic of Barcelona, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain",
    "16Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC",
    "17Department of Hematology, Ankara University, Ankara, Turkey",
    "18Fred Hutchinson Cancer Center, Seattle, WA",
    "19Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH",
    "20Clínica São Germano, São Paulo, Brazil",
    "21Department of Hematology and Hematopoietic Cell Transplantation, The Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA",
    "22Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus, OH",
    "23Département de Néphrologie et Transplantation d’Organes, Centre de Référence des Maladies Rénales Rares, Hôpital Rangueil, Centre Hospitalier Universitaire de Toulouse, Toulouse, France",
    "24Department of Medicine, Korea University, Seoul, Korea",
    "25Division of Hematology/Oncology, Columbia University Medical Center, New York, NY",
    "26Penn Amyloidosis Program, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA",
    "27Vanderbilt University Medical Center, Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN",
    "28Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI",
    "29Division of Hematology, London Health Sciences Centre, Verspeeten Family Cancer Centre, Western University, London, ON, Canada",
    "30Division of Hematology, Vancouver General Hospital, BC Cancer, University of British Columbia, Vancouver, Canada",
    "31Onkologicum Hämatologisch-Onkologische Praxis Altona, Hamburg, Germany",
    "32Department of Hematology, Centre Hospitalier Universitaire Lille, University of Lille, Lille, France",
    "33Amyloidosis Center of Expertise, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands",
    "34Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland",
    "35Department of Clinical Haematology, Westmead Hospital, Westmead, NSW, Australia",
    "36Department of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan",
    "37Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea",
    "38Clinica Centro de Hematologia e Oncologia, Rede D’Or Oncologia, Salvador, Brazil",
    "39Johnson & Johnson, Los Angeles, CA",
    "40Johnson & Johnson, Raritan, NJ"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 100,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Efstathios Kastritis",
      "orcid": "0000-0001-8191-5832"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Giovanni O. Palladini",
      "orcid": "0000-0001-5994-5138"
    },
    {
      "affs": [
        3
      ],
      "name": "Monique C. Minnema",
      "orcid": "0000-0002-3139-8379"
    },
    {
      "affs": [
        4
      ],
      "name": "Ashutosh D. Wechalekar",
      "orcid": "0000-0002-4406-7237"
    },
    {
      "affs": [
        5
      ],
      "name": "Arnaud Jaccard",
      "orcid": "0000-0001-7091-8253"
    },
    {
      "affs": [
        6
      ],
      "name": "Hans Chulhee Lee",
      "orcid": "0000-0001-8545-3292"
    },
    {
      "affs": [
        7
      ],
      "name": "Vaishali Sanchorawala",
      "orcid": "0000-0002-6307-2445"
    },
    {
      "affs": [
        8
      ],
      "name": "Peter N. Mollee",
      "orcid": "0000-0002-8537-1198"
    },
    {
      "affs": [
        9
      ],
      "name": "Jin Lu"
    },
    {
      "affs": [
        10
      ],
      "name": "Stefan O. Schönland"
    },
    {
      "affs": [
        11
      ],
      "name": "Moshe E. Gatt",
      "orcid": "0000-0002-9426-4482"
    },
    {
      "affs": [
        12
      ],
      "name": "Kenshi Suzuki",
      "orcid": "0000-0001-7132-5337"
    },
    {
      "affs": [
        13
      ],
      "name": "Kihyun Kim"
    },
    {
      "affs": [
        14
      ],
      "name": "M. Teresa Cibeira",
      "orcid": "0000-0001-7184-0718"
    },
    {
      "affs": [
        15
      ],
      "name": "Manisha Bhutani",
      "orcid": "0000-0002-9019-7438"
    },
    {
      "affs": [
        16
      ],
      "name": "Meral Beksaç",
      "orcid": "0000-0003-1797-8657"
    },
    {
      "affs": [
        17
      ],
      "name": "Edward N. Libby"
    },
    {
      "affs": [
        18
      ],
      "name": "Jason Neil Valent",
      "orcid": "0000-0001-5605-7020"
    },
    {
      "affs": [
        19
      ],
      "name": "Vânia Hungria",
      "orcid": "0000-0002-4327-1957"
    },
    {
      "affs": [
        20
      ],
      "name": "Michael Alan Rosenzweig",
      "orcid": "0000-0001-5158-5131"
    },
    {
      "affs": [
        21
      ],
      "name": "Naresh Bumma",
      "orcid": "0000-0002-0547-7831"
    },
    {
      "affs": [
        22
      ],
      "name": "Antoine Huart",
      "orcid": "0009-0002-3898-8731"
    },
    {
      "affs": [
        0,
        23
      ],
      "name": "Meletios Athanasios Dimopoulos",
      "orcid": "0000-0001-8990-3254"
    },
    {
      "affs": [
        24
      ],
      "name": "Divaya Bhutani",
      "orcid": "0000-0002-5482-7543"
    },
    {
      "affs": [
        25
      ],
      "name": "Adam Waxman"
    },
    {
      "affs": [
        26
      ],
      "name": "Stacey Ann Goodman",
      "orcid": "0000-0003-3324-8136"
    },
    {
      "affs": [
        27
      ],
      "name": "Jeffrey A. Zonder",
      "orcid": "0000-0002-1741-2795"
    },
    {
      "affs": [
        28
      ],
      "name": "Selay Lam",
      "orcid": "0009-0006-9753-7390"
    },
    {
      "affs": [
        29
      ],
      "name": "Kevin Song",
      "orcid": "0000-0003-0786-7961"
    },
    {
      "affs": [
        30
      ],
      "name": "Timon Hansen"
    },
    {
      "affs": [
        31
      ],
      "name": "Salomon Manier",
      "orcid": "0000-0001-7653-711X"
    },
    {
      "affs": [
        32
      ],
      "name": "Wilfried W. H. Roeloffzen",
      "orcid": "0000-0003-3976-8001"
    },
    {
      "affs": [
        33
      ],
      "name": "Krzysztof Jamroziak",
      "orcid": "0000-0001-7207-8534"
    },
    {
      "affs": [
        34
      ],
      "name": "Fiona Kwok"
    },
    {
      "affs": [
        35
      ],
      "name": "Chihiro Shimazaki",
      "orcid": "0000-0002-1006-7749"
    },
    {
      "affs": [
        36
      ],
      "name": "Jae‐Joong Kim",
      "orcid": "0000-0002-2714-2282"
    },
    {
      "affs": [
        37
      ],
      "name": "Edvan de Queiroz Crusoé",
      "orcid": "0000-0002-8599-4731"
    },
    {
      "affs": [
        38
      ],
      "name": "NamPhuong Tran"
    },
    {
      "affs": [
        39
      ],
      "name": "Jianping Wang"
    },
    {
      "name": "Yuping Chen"
    },
    {
      "name": "Sandra Y. Vasey"
    },
    {
      "affs": [
        39
      ],
      "name": "Jordan Mark Schecter",
      "orcid": "0000-0001-5849-0987"
    },
    {
      "name": "JESSICA T. VERMEULEN"
    },
    {
      "name": "Raymond L. Comenzo",
      "orcid": "0000-0002-6255-5824"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Giampaolo Merlini",
      "orcid": "0000-0001-7680-3254"
    },
    {
      "name": "Bradley M. Augustson",
      "orcid": "0009-0008-0072-2579"
    },
    {
      "affs": [
        34
      ],
      "name": "Fiona Kwok"
    },
    {
      "affs": [
        8
      ],
      "name": "Peter Mollee"
    },
    {
      "name": "Simon DJ Gibbs",
      "orcid": "0000-0002-1244-4106"
    },
    {
      "name": "Chantal Doyen"
    },
    {
      "name": "Greet Bries"
    },
    {
      "name": "Isabelle Vande Broek",
      "orcid": "0009-0003-7923-7149"
    },
    {
      "name": "Ka Lung Wu",
      "orcid": "0000-0001-6042-978X"
    },
    {
      "name": "Koen Theunissen"
    },
    {
      "name": "Koen Van Eygen",
      "orcid": "0000-0001-8285-906X"
    },
    {
      "name": "Michel Delforge",
      "orcid": "0000-0002-0147-2291"
    },
    {
      "name": "Nathalie Meuleman",
      "orcid": "0000-0003-0479-2474"
    },
    {
      "name": "Philip Vlummens",
      "orcid": "0000-0001-8275-2887"
    },
    {
      "name": "Ângelo Maiolino",
      "orcid": "0000-0003-0140-9548"
    },
    {
      "name": "Breno Moreno De Gusmão",
      "orcid": "0000-0001-7209-4665"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/ejrc8ae260erg.bib",
  "cited_by": 19,
  "doi": "10.1182/blood.2025032099",
  "fulltext_url": null,
  "id": "ejrc8ae260erg",
  "issns": [
    "0006-4971",
    "1528-0020"
  ],
  "landing_url": "https://doi.org/10.1182/blood.2025032099",
  "language": "en",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "1312|Amyloidosis: Diagnosis, Treatment, Outcomes"
    ]
  ],
  "openalex": "W7160955961",
  "pdf_url": null,
  "pmcid": "PMC13598864",
  "pmid": "42118698",
  "published": "2026-05-12",
  "publisher": "Elsevier BV",
  "ris": "https://research.draconitic.com/paper/ejrc8ae260erg.ris",
  "sources": [
    {
      "first_seen": "2026-11-04T13:21:05Z",
      "native_id": "W7160955961",
      "source": "openalex",
      "url": "https://doi.org/10.1182/blood.2025032099"
    }
  ],
  "subjects": [
    {
      "field": "biochemistry",
      "origin": "openalex:1312|Amyloidosis: Diagnosis, Treatment, Outcomes",
      "subfield": "molecular-biology"
    }
  ],
  "title": "Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis",
  "title_text": "Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis",
  "type": "peer-reviewed",
  "updated_at": "2026-11-04T13:21:05Z",
  "url": "https://research.draconitic.com/paper/ejrc8ae260erg",
  "venue": "Blood",
  "versions": []
}